Suppr超能文献

速尿和白蛋白利尿治疗水肿(FADE):一项平行分组、盲法、先导随机对照试验。

Furosemide and Albumin for Diuresis of Edema (FADE): A parallel-group, blinded, pilot randomized controlled trial.

机构信息

Division of Critical Care Medicine, Department of Medicine, McMaster University, Canada; Department of Critical Care, Hamilton Health Sciences, Canada.

Department of Critical Care, Hamilton Health Sciences, Canada.

出版信息

J Crit Care. 2018 Dec;48:462-467. doi: 10.1016/j.jcrc.2018.07.020. Epub 2018 Jul 19.

Abstract

PURPOSE

To assess the feasibility of a trial evaluating whether hyperoncotic albumin, in addition to diuretics, improves diuresis and facilitates liberation from mechanical ventilation in critically ill adults.

MATERIALS AND METHODS

We randomized 46 hemodynamically stable patients with hypoalbuminemia, prescribed diuretics by treating clinicians, to receive 100 mL of 25% albumin or 0.9% saline placebo BID, for three days, in blinded fashion. We chose five feasibility measurements: enrolment of 50% of eligible patients, at least one patient/week; administration of study treatment within 2 h of diuretics in 85% of patients; completion of study regimen in 80% of patients; and avoidance of open label albumin in 85% of patients. Clinical outcomes included fluid balance, ventilator-free days, and mortality.

RESULTS

We randomized 85% of eligible patients. Eighty-four percent received study treatment within 2 h of diuretics, 69% received all doses of study treatment. Study treatment was held in the albumin and placebo groups because of no further need for diuresis (4 vs. 1), hypotension (2 v. 4), and albumin > 35 (1 v. 0). Twenty percent of patients received open-label albumin. Clinical outcomes were similar between groups.

CONCLUSIONS

The current study design did not demonstrate feasibility, but can inform the design of a definitive trial.

摘要

目的

评估一项试验的可行性,该试验旨在评估在危重症成人中,除利尿剂外,高渗白蛋白是否能增加利尿作用并促进机械通气撤离。

材料和方法

我们将 46 名血流动力学稳定且低白蛋白血症的患者随机分为两组,接受治疗医生开具的利尿剂治疗,并以盲法的方式分别接受 100ml 25%白蛋白或 0.9%生理盐水安慰剂,每天 2 次,持续 3 天。我们选择了 5 项可行性测量指标:入组符合条件的患者的 50%;每周至少有 1 名患者;85%的患者在接受利尿剂治疗后 2 小时内给予研究治疗;80%的患者完成研究方案;85%的患者避免使用白蛋白。临床结局包括液体平衡、无呼吸机天数和死亡率。

结果

我们随机分配了 85%的符合条件的患者。84%的患者在接受利尿剂治疗后 2 小时内接受了研究治疗,69%的患者接受了所有剂量的研究治疗。由于不再需要利尿(4 例 vs. 1 例)、低血压(2 例 vs. 4 例)和白蛋白>35g/L(1 例 vs. 0 例),白蛋白组和安慰剂组各有 1 例和 4 例患者停止了研究治疗。20%的患者接受了开放标签白蛋白治疗。两组的临床结局相似。

结论

目前的研究设计并未显示出可行性,但可为确定试验的设计提供信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验